Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIZM study of zagociguat in MELAS
2024-515389-15-00Phase 2Completed
- Sponsor
- Tisento Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of zagociguat in mitochondrial encephalomyopathies (2 arms), sponsored by Tisento Therapeutics. Primary endpoints: Global statistical test of fatigue and cognition and Treatment-emergent adverse events. Started Oct 2024; status: completed.
02
Drugs
zagociguat
03
Conditions
mitochondrial encephalomyopathies
Beyond the preview
Go deeper on 2024-515389-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515389-15-00.